T-DXd
Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier and distribution to tumor cells in HER2+ brain metastasis model systems
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
T-DXd
Colorectal Cancer
Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: A plain language summary of the DESTINY-CRC02 study
Raghav K.
Future Oncol. 2026 Jan;22(2):123-135. doi: 10.1080/14796694.2025.2606418.
Pipeline Compounds
Other/Multi
DS-3939a: A TA-MUC1-directed antibody-drug conjugate with broad antitumor activity
Takano K, Yukiura M, Takahashi K, et al.
Mol Cancer Ther. 2026 Jan 2;25(1):7-20. doi: 10.1158/1535-7163.MCT-24-0666.
Edoxaban
Cardiovascular - AF
Patient-reported outcomes using win ratio analysis: A post hoc analysis from the randomized ENVISAGE-TAVI AF trial
Hengstenberg C, Van Mieghem NM, Wang R, et al.
Am J Cardiol. 2026 Mar 15;263:63-68. doi: 10.1016/j.amjcard.2025.12.016.
T-DXd
Breast Cancer
Lung Cancer
Other/Multi
Characterization of the safety profile of trastuzumab deruxtecan by dose: A pooled analysis across DESTINY studies.
Park YH, Cortes J, Modi S, et al.
Oncologist. 2025 Dec 27;31(1):oyaf396. doi: 10.1093/oncolo/oyaf396.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study
Pistilli B, Jhaveri K, Im SA, et al.
Ann Oncol. 2025 Dec 23:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.12.017.
Dato-DXd
Lung Cancer
TROPION-Lung15: A randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib
Tan DS, Nadal E, Cheema P, et al.
Ther Adv Med Oncol. 2025 Dec 23;17:17588359251385410. doi: 10.1177/17588359251385410.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in patients with HER2-overexpressing NSCLC: Results from part 1 of the open-label, multicenter, phase 1b DESTINY-Lung03 trial
Planchard D, Kim HR, Suksombooncharoen T, et al.
J Thorac Oncol. 2025 Dec 23:103541. doi: 10.1016/j.jtho.2025.12.080.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in residual HER2-positive early breast cancer
Loibl S, Park YH, Shao Z, et al.
N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661.
T-DXd
Gastric Cancer
Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: A postmarketing surveillance study in Japan
Kawakami H, Uchino K, Hashimoto W, Muro K.
ESMO Open. 2025 Dec;10(12):105914. doi: 10.1016/j.esmoop.2025.105914.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below